X4 Pharmaceuticals Inc
XFOR
Company Profile
Business description
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company’s lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
Contact
61 North Beacon Street
4th Floor
BostonMA02134
USAT: +1 857 529-8300
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
143
Stocks News & Analysis
stocks
Chart of the Week: The market may be underestimating Amcor’s long term potential
Our latest stock pitch.
stocks
Competitive pressures highlight need to lower costs for big 4 bank
Market reacts positively to results.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,034.50 | 50.40 | -0.55% |
| CAC 40 | 8,232.49 | 8.75 | -0.11% |
| DAX 40 | 24,041.62 | 339.84 | -1.39% |
| Dow JONES (US) | 47,457.22 | 797.60 | -1.65% |
| FTSE 100 | 9,807.68 | 103.74 | -1.05% |
| HKSE | 27,073.03 | 150.30 | 0.56% |
| NASDAQ | 22,870.36 | 536.10 | -2.29% |
| Nikkei 225 | 51,281.83 | 218.52 | 0.43% |
| NZX 50 Index | 13,533.00 | 64.87 | -0.48% |
| S&P 500 | 6,737.49 | 113.43 | -1.66% |
| S&P/ASX 200 | 8,753.40 | 46.00 | -0.52% |
| SSE Composite Index | 4,029.50 | 29.36 | 0.73% |